Class summary at a glance.

Every drug in the CD30-directed Immunoconjugate class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $6.5Mcombined across class
Total Rx claims: 18347 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Brentuximab Vedotin

Brand: ADCETRIS · 183 Part D claims (CY24) · 47 beneficiaries · First FDA approval: 2011-08-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $6.5M

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.